Drugs / AVR-48
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06847698 | Jun → Oct 2025 overdue | — | AyuVis Research, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVR-48 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06847698 ↗ |
| Modality | Small molecule | “AVR-48 is a small molecule with TLR4 modulating activity and macrophage modulator” NCT06847698 ↗ |
| Route | Intravenous | “Investigational drug reconstituted in normal saline will be administered via IV” NCT06847698 ↗ |
| Target | TLR4 | “AVR-48 is a small molecule with TLR4 modulating activity and macrophage modulator” NCT06847698 ↗ |